Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,046

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057

Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs

Obenauer, J. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg584 · Cited by 1,609

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355

PD-1 and PD-1 ligands: from discovery to clinical application

Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307

Association of TIM-3 expression with glucose metabolism in Jurkat T cells

Lee, M. J., Yun, S. J., Lee, B., Jeong, E., Yoon, G., Kim, K. H., & Park, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00377-6 · Cited by 47

Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy

Meggyes, M., Lajko, A., Palkovics, T., Totsimon, A., Illés, Z., Szereday, L., & Mikó, É. (2015) · Placenta · doi:10.1016/j.placenta.2015.07.124 · Cited by 43

Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?

Khosroshahi, L. M., Parhizkar, F., Kachalaki, S., Aghebati‐Maleki, A., & Maleki, L. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107935 · Cited by 43

Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells

Cong, Y., Cui, Y., Zhu, S., Cao, J., Zou, H., Martin, T. A., Qiao, G., Jiang, W. G., & Yu, Z. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.05.02 · Cited by 42

TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1

Chi-Sabins, N., Chornoguz, O., Leander, K. R., Kaplan, F. M., Carter, R., Kinder, M., Bachman, K. E., Verona, R. I., Shen, S., Bhargava, V., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701030 · Cited by 41

Regulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3)

Pfeifhofer‐Obermair, C., Tymoszuk, P., Nairz, M., Schroll, A., Klais, G., Demetz, E., Engl, S., Brigo, N., & Weiß, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637809 · Cited by 41

Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion

Zhu, C., Dixon, K. O., Newcomer, K., Gu, G., Xiao, S., Zaghouani, S., Schramm, M. A., Wang, C., Zhang, H., Goto, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd2710 · Cited by 40

Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer

Bauer, C. A., Kühnemuth, B., Duewell, P., Ormanns, S., Gress, T. M., & Schnurr, M. M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.057 · Cited by 41

On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment

Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 41

Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance

Ocaña‐Guzmán, R., Vazquez-Bolaños, L. A., & Sada‐Ovalle, I. (2018) · Journal of Immunology Research · doi:10.1155/2018/8695157 · Cited by 40

Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies

Stachyra, K., Dudzisz‐Śledź, M., Bylina, E., Szumera‐Ciećkiewicz, A., Spalek, M. J., Bartnik, E., Rutkowski, P. L., & Czarnecka, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126305 · Cited by 40

Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection

Nunes-Alves, C., Booty, M. G., Carpenter, S. M., Rothchild, A. C., Martin, C. J., Desjardins, D., Steblenko, K. M., Kløverpris, H. N., Madansein, R., Ramsuran, D., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004849 · Cited by 40

B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation

Singh, M. D., Ni, M., Sullivan, J. M., Hamerman, J. A., & Campbell, D. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171820 · Cited by 38

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

Batista-Duharte, A., Hassouneh, F., Álvarez-Heredia, P., Pera, A., & Solana, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081721 · Cited by 37

The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells

Zhang, J., Wang, L., Guo, H., Kong, S., Li, W., He, Q., Ding, L., & Yang, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107458 · Cited by 38

Unraveling the Role of Immune Checkpoints in Leishmaniasis

Silva, R. D. F. E., & von Stebut, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.620144 · Cited by 37

Translation of cancer immunotherapy from the bench to the bedside

Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 35

TIM‐3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways

Kikushige, Y. (2021) · Cancer Science · doi:10.1111/cas.15042 · Cited by 36

The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy

Yang, R., & Hung, M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9176-7 · Cited by 35

Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction

Moriyama, K., Kukita, A., Li, Y.-J., Uehara, N., Zhang, J.-Q., Takahashi, I., & Kukita, T. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.107 · Cited by 35

Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)

Rietz, T. A., Teuscher, K. B., Mills, J. J., Gogliotti, R. D., Lepovitz, L. T., Scaggs, W. R., Yoshida, K., Luong, K., Lee, T., & Fesik, S. W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01336 · Cited by 35

Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3

Yang, X., Li, M., Qin, X., Tan, S., Du, L., Ma, C., & Li, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11498 · Cited by 35

Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening

Abdel‐Rahman, S. A., Talagayev, V., Pach, S., Wolber, G., & Gabr, M. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00960 · Cited by 33

HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 + T Cells

Prévost, J., Edgar, C. R., Richard, J., Trothen, S. M., Jacob, R. A., Mumby, M. J., Pickering, S., Dubé, M., Kaufmann, D., Kirchhoff, F., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01999-19 · Cited by 36

The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets

Zhou, X., Ren, T., Zan, H., Hua, C., & Guo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864202 · Cited by 33

TIM‐3 and CEACAM1 do not interact in cis and in trans

Linhares, A. D. S., Kellner, F., Jutz, S., Zlabinger, G. J., Gabius, H., Huppa, J. B., Leitner, J. M., & Steinberger, P. (2020) · European Journal of Immunology · doi:10.1002/eji.201948400 · Cited by 32

Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells

Chi-Sabins, N., Harman, B. C., Barone, L. R., Shen, S., & Santulli-Marotto, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00221 · Cited by 31

Immune checkpoint receptors in cancer: redundant by design?

Li, J., Ni, L., & Dong, C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.001 · Cited by 31

Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity

Riva, A., Palma, E., Devshi, D., Corrigall, D., Adams, H., Heaton, N. D., Menon, K., Preziosi, M., Zamalloa, A., Miquel, R., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.632502 · Cited by 31

Enhanced Tim3 Activity Improves Survival after Influenza Infection

Cho, J. L., Roche, M. I., Sandall, B. P., Brass, A. L., Seed, B., Xavier, R. J., & Medoff, B. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102483 · Cited by 29

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies

Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29

Transcriptomic Profiling of Tumor-Infiltrating CD4+TIM-3+ T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients

Nair, V. S., Toor, S. M., Taha, R. Z., Ahmed, A., Kurer, M. A., Murshed, K., Soofi, M. E., Ouararhni, K., Alajez, N. M., Nada, M. A., et al. (2020) · Vaccines · doi:10.3390/vaccines8010071 · Cited by 30

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes

Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 29

TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation

Dao, T. N., Utturkar, S. M., Lanman, N. A., & Matosevic, S. (2020) · Cancers · doi:10.3390/cancers12092417 · Cited by 29

Opposing regulatory functions of the TIM3 (HAVCR2) signalosome in primary effector T cells as revealed by quantitative interactomics

Zhai, Y., Celis‐Gutierrez, J., Voisinne, G., Mori, D., Girard, L., Burlet‐Schiltz, O., de Peredo, A. G., Roncagalli, R., & MALISSEN, B. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00575-7 · Cited by 28

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29

Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis

Schatton, T., Itoh, Y., Martins, C. P., Rasbach, E., Singh, P. K., Silva, M., Mucciarone, K., Heppt, M. V., Geddes-Sweeney, J., Stewart, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0970 · Cited by 28

Polyfunctional natural killer cells with a low activation profile in response to Toll-like receptor 3 activation in HIV-1-exposed seronegative subjects

de Lima, J. F., Oliveira, L. M. D. S., Pereira, N. Z., Duarte, A. J. S., & Sato, M. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-00637-3 · Cited by 28

Down-regulation of interleukin-2 production by CD4+ T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription

Lee, M. J., Woo, M.-Y., Chwae, Y., Kwon, M., Kim, K. H., & Park, S. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.01.012 · Cited by 27

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

Hu, Q., Shi, Y., Wang, H., Li, B., & Xu, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00627-6 · Cited by 27

Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy

Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 28

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies

Krug, A., Martinez-Turtos, A., & Verhoeyen, E. (2021) · Cancers · doi:10.3390/cancers14010183 · Cited by 28

Microglia activity modulated by T cell Ig and mucin domain protein 3 (Tim-3)

Wang, H., Zhu, X., Qin, L., Qian, H.-J., & Wang, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.005 · Cited by 26

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma

Zhang, X., Yin, X., Zhang, H., Sun, G., Yang, Y., Chen, J., Shu, K., Zhao, J., Zhao, P., Chen, N., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5273-5 · Cited by 25

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Commonγ-Chain Cytokines

Zhang, Z., Zhu, M.-L., Chen, Y., Fu, Y., Zhang, T.-W., Jiang, Y., Chu, Z., & Shang, H. (2015) · BioMed Research International · doi:10.1155/2015/916936 · Cited by 25

TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1

Lake, C. M., Voss, K., Bauman, B. M., Pohida, K., Jiang, T., Dveksler, G. S., & Snow, A. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03689-6 · Cited by 23

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Blaeschke, F., Ortner, E., Stenger, D., Mahdawi, J., Apfelbeck, A., Habjan, N., Weißer, T., Kaeuferle, T., Willier, S. M., Kobold, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845499 · Cited by 24

Influence of T Cell Coinhibitory Molecules on CD8+ Recall Responses

Morris, A. B., Adams, L. E., & Ford, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01810 · Cited by 23

Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors

Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 22

TIM3 expression by leukemic and non‐leukemic myeloblasts

Roth, C. G., Garner, K., Eyck, S. T., Boyiadzis, M. M., Kane, L., & Craig, F. E. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21080 · Cited by 22

MiR-155 inhibits transformation of macrophages into foam cells via regulating CEH expression

Zhang, F., Zhao, J., Sun, D., & Wei, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.068 · Cited by 22

TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak

Rozalén, C., Sangrador, I., Avalle, S., Blasco-Benito, S., Tzortzi, P., Sanz‐Flores, M., Palomeque, J. Á., Torren-Duran, P., Dalmau, M., Brunel, H., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.015 · Cited by 21

Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1 Infected Children

Tandon, R., Giret, M. T. M., SenGupta, D., York, V. A., WIZNIA, A. A., Rosenberg, M. G., Kallas, E. G., Ndhlovu, L. C., & Nixon, D. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045733 · Cited by 21

Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity

Dou, S., Li, G., Li, G., Hou, C., Zheng, Y., Tang, L., Gao, Y., Mo, R., Li, Y., Wang, R., et al. (2021) · eLife · doi:10.7554/elife.66501 · Cited by 21

Novel Roles of the Tim Family in Immune Regulation and Autoimmune Diseases

Liu, Y., Chen, H., Chen, Z., Qiu, J., Pang, H., & Zhou, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748787 · Cited by 21

Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing

Mangelinck, A., Dubuisson, A., Becht, É., Dromaint, S., Fasquel, M., Provost, N., Walas, D., Darville, H., Galizzi, J., Lefèbvre, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1320481 · Cited by 21

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors

Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 20

Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells

Tardos, E. C., Baglioni, M. V., & Bekiaris, V. (2021) · Cancers · doi:10.3390/cancers13184647 · Cited by 20

Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential

Saleh, R., Toor, S. M., & Elkord, E. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1841750 · Cited by 19

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy

Lak, S., Janelle, V., Djedid, A., Boudreau, G., Brasey, A., Lisi, V., Smaani, A., Carli, C., Busque, L., Lavallée, V., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.016 · Cited by 19

Extracellular vesicles derived from nasopharyngeal carcinoma induce the emergence of mature regulatory dendritic cells using a galectin‐9 dependent mechanism

Lefebvre, A., Trioën, C., Renaud, S., Laine, W., Hennart, B., Bouchez, C., Leroux, B., Allorge, D., Kluza, J., Werkmeister, E., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12390 · Cited by 19

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets

Vilela, T., Valente, S., Correia, J., & Ferreira, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189144 · Cited by 19

TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer

Attalla, K., Farkas, A. M., Anastos, H., Audenet, F., Galsky, M. D., Bhardwaj, N., & Sfakianos, J. P. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.06.007 · Cited by 19

Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients

Peter, L., Wendering, D. J., Schlickeiser, S., Hoffmann, H., Noster, R., Wagner, D. L., Zarrinrad, G., Münch, S., Picht, S., Schulenberg, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.012 · Cited by 19

Killer instincts: natural killer cells as multifactorial cancer immunotherapy

Nersesian, S., Carter, E. B., Lee, S. N., Westhaver, L. P., & Boudreau, J. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269614 · Cited by 20

Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 18

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease

Flies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 18

Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications

Hsieh, H.-C., Ling, L.-L., & Yi-Ching, W. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01202-1 · Cited by 17

Acute stimulation generates Tim‐3‐expressing T helper type 1 CD 4 T cells that persist in vivo and show enhanced effector function

Gorman, J. V., & Colgan, J. D. (2018) · Immunology · doi:10.1111/imm.12890 · Cited by 17

The immunological effect of Galectin-9/TIM-3 pathway after low dose Mifepristone treatment in mice at 14.5 day of pregnancy

Lajko, A., Meggyes, M., Polgár, B., & Szereday, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194870 · Cited by 17

Tim‐3 blockade promotes iNKT cell function to inhibit HBV replication

Xu, Y., Wang, Z., Du, X., Liu, Y., Song, X., Wang, T., Tan, S., Liang, X., Gao, L., & Ma, C. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13600 · Cited by 16

Targeting novel inhibitory receptors in cancer immunotherapy

Ding, Q., Chauvin, J.-M., & Zarour, H. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101436 · Cited by 16

Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3

Weber, J. K., & Zhou, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-14064-x · Cited by 15

Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy

Cao, Y., Li, Q., Liu, H., He, X., Huang, F., & Wang, Y. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210114 · Cited by 15

The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells

Jacob, R. A., Edgar, C. R., Prévost, J., Trothen, S. M., Lurie, A., Mumby, M. J., Galbraith, A., Kirchhoff, F., Haeryfar, S. M. M., Finzi, A., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101042 · Cited by 15

Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization

Edmunds, G. L., Wong, C. C. W., Ambler, R., Milodowski, E., Alamir, H., Cross, S., Galea, G., Wülfing, C., & Morgan, D. J. (2022) · Communications Biology · doi:10.1038/s42003-021-02972-8 · Cited by 14

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Harrington, P., Dillon, R. J., Radia, D. H., Rousselot, P. H., McLornan, D. P., Ong, M., Green, A. C., Verde, A., Hussain, F., Raj, K. K., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282005 · Cited by 14

The evaluation of PD-1 and Tim-3 expression besides their related miRNAs in PBMCs of women with recurrent pregnancy loss

Ahmadi, H., Soltani‐Zangbar, M. S., Yousefi, M., Baradaran, B., Bromand, S., Maleki, L. A., & Szekeres‐Barthó, J. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106837 · Cited by 14

Monoclonal antibody against human Tim‐3 enhances antiviral immune response

Li, G., Hou, C., Dou, S., Zhang, J., Zhang, Y., Liu, Y., Wang, Z., He, X., Wang, R., Chen, G., et al. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12738 · Cited by 14

The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment

Hemmatzadeh, M., Parvin, E. A., Mohammadi, H., Azizi, G., Shomali, N., & Jadidi‐Niaragh, F. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30855 · Cited by 15

The Role of TIM-3 in Glioblastoma Progression

Ahmady, F., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2025) · Cells · doi:10.3390/cells14050346 · Cited by 14

Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity

Waugh, K. A., Leach, S. M., & Slansky, J. E. (2015) · Vaccines · doi:10.3390/vaccines3030771 · Cited by 14

Comparative analysis of decidual and peripheral immune cells and immune‐checkpoint molecules during pregnancy in wild‐type and PACAP‐deficient mice

Lajko, A., Meggyes, M., Fulop, B. D., Gede, N., Reglődi, D., & Szereday, L. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.13035 · Cited by 13

Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment

Capitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 15

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets

Reeves, E. P., Vega-Carrascal, & McElvaney, N. G. (2012) · Journal of Inflammation Research · doi:10.2147/jir.s34225 · Cited by 13

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 12

Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1

Yado, S., Dassa, B., Zoabi, R., Reich-Zeliger, S., Friedman, N., & Geiger, B. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009011 · Cited by 12

TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1

Shapourian, H., Ghanadian, M., Eskandari, N., Shokouhi, A., Demirel, G. Y., Bazhin, A. V., & Ganjalıkhani-Hakemi, M. (2024) · BMC Cancer · doi:10.1186/s12885-024-11898-3 · Cited by 12

Generation and Characterization of Recombinant Pseudorabies Virus Delivering African Swine Fever Virus CD2v and p54

Wei, J., Liu, C., He, X., Abbas, B., Chen, Q., Li, Z., & Feng, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010335 · Cited by 11

Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding

Meng, X., Luo, Y., Cui, L., & Wang, S. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.106115 · Cited by 11

Negative Regulation of RIG-I by Tim-3 Promotes H1N1 Infection

Shi, Q., Li, G., Dou, S., Tang, L., Hou, C., Wang, Z., Gao, Y., Gao, Z., Hao, Y., Mo, R., et al. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2113407 · Cited by 11

TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3

Kim, K. S., Lee, C., Kim, H.-S., Gu, S. J., Yoon, H. J., Won, S. B., Lee, H., Lee, Y. S., Kim, S. S., Kane, L., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06762-w · Cited by 10

Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy

Kent, A., Longino, N. V., Christians, A. J., & Dávila, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658611 · Cited by 11

The study of immune checkpoint inhibitors in chronic hepatitis B virus infection

Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., Jiaqiang, Y., Lv, J., Dong, L., Yu, G., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108842 · Cited by 11

Patients with intracranial aneurysms presented defects in regulatory T cells, which were associated with impairment in Tim-3 upregulation

Zhang, H., Liang, G., Zhao, M., Zhao, G.-F., & Luo, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.09.020 · Cited by 10

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review

Ocaña‐Guzmán, R., Osorio-Pérez, D., & Chávez‐Galán, L. (2023) · Pharmaceuticals · doi:10.3390/ph16081119 · Cited by 9

Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition

Suen, T. K., Al, B., Ulas, T., Reusch, N., Bahrar, H., Bekkering, S., Bhat, J., Kabelitz, D., Schultze, J. L., van de Veerdonk, F. L., et al. (2025) · Immunology · doi:10.1111/imm.13931 · Cited by 9

TIM3 is a context-dependent coregulator of cytotoxic T cell function

Alamir, H., Wong, C. C. W., Alsubaiti, A., Edmunds, G. L., Alismail, M., Huynh, L., Shi, Y., Lewis, P. A., Grant, T., Alsulaimani, S., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adk4594 · Cited by 9

Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy

Dadfar, S., Eivazzadeh, Y., Molavi, H., Abedi, H., Razavi, F. T., & Haghmorad, D. (2026) · Inflammation Research · doi:10.1007/s00011-026-02211-y · Cited by 9

Mechanisms of Tim-3 Signal Transduction in the Modulation of Downstream TCR Signaling

Lee, J. (2013) · D-Scholarship@Pitt (University of Pittsburgh)

The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse

Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 52

The co-stimulatory activity of Tim-3 requires Akt and MAPK signaling and immune synapse recruitmentPreprint

Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.30.878520 · Cited by 1

Determination of Cytoplasmic Tyrosine Residues of Tim-3 Involved in Regulation of TCR signaling (35.30)

Lee, J., Su, E. W., Phuah, J. Y., Hainline, S. G., & Kane, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.supp.35.30 · Cited by 1

Abstract PO032: TIM3 regulation by phosphatidylserine

Smith, C. M., Li, A., Krishnamurthy, N., & Lemmon, M. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm20-po032